Dana-Farber Cancer Institute: Graft vs Host Disease trials

The registry lists 22 Graft vs Host Disease studies with Dana-Farber Cancer Institute as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 6Phase 2 15Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• IS-free Treg HaploHCTRecruitingNCT04678401Phase 1
• Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT03717480Phase 2Results posted
• Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell TransplantationCompletedNCT02867384Phase 2Results posted
• Gut Decontamination In Pediatric Allogeneic HematopoieticCompletedNCT02641236Phase 2Results posted
• Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHDCompletedNCT02176031Phase 2Results posted
• An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-DiseaseTerminatedNCT02123966Phase 2Results posted
• Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell TransplantCompletedNCT01754389Phase 2Results posted
• Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host DiseaseTerminatedNCT01226420Phase 2Results posted
• Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host DiseaseCompletedNCT00815919Phase 2Results posted
• Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell TransplantationTerminatedNCT00548717Phase 2Results posted
• Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host DiseaseCompletedNCT00529035Phase 1Results posted
• Campath in Chronic GVHDCompletedNCT00495755Phase 1Results posted
• Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationCompletedNCT00369226Phase 1/2Results posted
• Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell TransplantationCompletedNCT00282282Phase 2Results posted
• Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART TrialActive, not recruitingNCT05236062Not applicable
• Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host DiseaseCompletedNCT01221766
• Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell TransplantationCompletedNCT00146614Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
• Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host DiseaseCompletedNCT00136396Phase 1/2
• Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host DiseaseCompletedNCT00053976Phase 3
• Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous TherapyCompletedNCT00005988Phase 1